Angel Biotechnology Holdings Plc Angel sign new contract with ReNeuron (2534Q)
05 Noviembre 2012 - 1:00AM
UK Regulatory
TIDMABH
RNS Number : 2534Q
Angel Biotechnology Holdings Plc
05 November 2012
5 November 2012
Angel Biotechnology Holdings plc
("Angel" or "the Group")
Manufacturing Contract for ReNeuron Drug Substance
Angel Biotechnology Holdings plc, (AIM:ABH), the
biopharmaceutical contract manufacturer, is pleased to announce the
signing of a new contract with ReNeuron Group plc. This contract
relates to the expansion of CTX cells, the production of a GMP Drug
Substance batch and associated testing. The contract is scheduled
for completion in the current financial year.
Mr Nicholas Smith, Non-Executive Chairman of Angel said: "Angel
continues to build on its track record of providing its expertise
and services to ReNeuron Group plc. The new contract will
demonstrate Angel's ongoing ability to respond to the needs of its
clients to provide high quality, reliable and value-for-money
services."
Mr Michael Hunt, CEO of ReNeuron Group plc said: "Angel remains
a key player in the supply chain of our clinical material. This
contract will ensure the provision of further Drug Substance
material required to service our on-going therapeutic programmes.
"
For further information:
Angel Biotechnology Holdings plc
Nicholas Smith, Non-Executive Chairman +44 (0) 131 445 6077
www.angelbio.com
Grant Thornton, Corporate Finance
Colin Aaronson / Melanie Frean +44 (0) 20 7383 5100
Hybridan LLP (Broker)
Claire Noyce, Deepak Reddy +44 (0) 20 7947 4350
Media enquiries:
The Communications Portfolio Ltd
Philip Ranger / Caolan Mahon +44 (0) 20 7536 2028 / 2029
Notes to Editors:
Angel Biotechnology Holdings plc is a full service contract
bio-manufacturing partner to biotechnology and pharmaceutical
companies worldwide. Angel specialises in advanced biologics
including biopharmaceutical proteins and cell therapies, such as
cellular vaccines and stem cells. At present, Angel's products are
principally used in pre-clinical studies and clinical trials with a
view to becoming the contract manufacturer of choice on a
continuing basis.
Drug development companies outsource their biopharmaceutical
manufacturing requirements to Angel to reduce their own capital
requirements and enable them to develop products more rapidly. In
addition, Angel provides complete regulatory services and
documentation to its customers while its manufacturing processes
adhere to the most stringent regulatory requirements. Products are
produced to current Good Manufacturing Practice (cGMP) standards as
required by the US Food and Drug Administration (FDA) and in
facilities that are certified to European standards by the
Medicines and Healthcare products Regulatory Agency (MHRA).
Its customers range from pioneering biotechnology companies such
as ReNeuron Group plc to established pharmaceutical companies such
as Russian-based Materia Medica Holdings.
Angel has three facilities: Pentlands Science Park near
Edinburgh, a site in Cramlington, near Newcastle-upon-Tyne and
Angel Biomedical Ltd facility in Glasgow.
More information is available at www.angelbio.com .
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBUBDBDBGBGDD
Angel Biotechnology (LSE:ABH)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Angel Biotechnology (LSE:ABH)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024